New study tracks rare disease SCA7 to uncover clues for future treatments
NCT ID NCT02741440
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 8 times
Summary
This study follows 25 people with spinocerebellar ataxia type 7 (SCA7) for up to 5 years to learn how the disease changes vision, coordination, and thinking. Participants will have yearly eye exams, brain scans, and neurological tests. No treatment is given; the goal is to gather data that could help design future therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINOCEREBELLAR ATAXIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict how genetic ataxias progress?
- Scientists decode gait signatures to spot brain diseases
- Could stem cells help people with spinocerebellar ataxia?
- New hope for SCA patients: expanded access to investigational drug troriluzole
- Could a drug slow rare brain disease? new study uses Real-World data to find out
- New study sheds light on vision loss in rare genetic brain disorders